A prospective study investigating the effect of sunitinib and association of clinical response with peripheral blood immune cells and serum inflammatory markers in patients with metastatic renal cell carcinoma

Trial Profile

A prospective study investigating the effect of sunitinib and association of clinical response with peripheral blood immune cells and serum inflammatory markers in patients with metastatic renal cell carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top